Augustine Kunle Obisesan

Array ( [id] => 19722725 [patent_doc_number] => 20250025476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/905520 [patent_app_country] => US [patent_app_date] => 2024-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18905520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19883014 [patent_doc_number] => 12268696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders [patent_app_type] => utility [patent_app_number] => 18/905502 [patent_app_country] => US [patent_app_date] => 2024-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 19681 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18905502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19722726 [patent_doc_number] => 20250025477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/905534 [patent_app_country] => US [patent_app_date] => 2024-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18905534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20106942 [patent_doc_number] => 12357640 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Pharmaceutical compositions comprising meloxicam [patent_app_type] => utility [patent_app_number] => 18/895044 [patent_app_country] => US [patent_app_date] => 2024-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 20036 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18895044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19898005 [patent_doc_number] => 12275914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Electronic inhalation device [patent_app_type] => utility [patent_app_number] => 18/892179 [patent_app_country] => US [patent_app_date] => 2024-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 48723 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18892179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743888 [patent_doc_number] => 20250032453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/891536 [patent_app_country] => US [patent_app_date] => 2024-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18891536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496418 [patent_doc_number] => 20240335436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST [patent_app_type] => utility [patent_app_number] => 18/745002 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19938843 [patent_doc_number] => 12310956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Topical roflumilast formulation having improved delivery and plasma half-life [patent_app_type] => utility [patent_app_number] => 18/653662 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 6680 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331348 [patent_doc_number] => 20240245778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS [patent_app_type] => utility [patent_app_number] => 18/594194 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402257 [patent_doc_number] => 20240285768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS [patent_app_type] => utility [patent_app_number] => 18/594172 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19960262 [patent_doc_number] => 12329734 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow [patent_app_type] => utility [patent_app_number] => 18/592262 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 6416 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18592262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402256 [patent_doc_number] => 20240285767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS [patent_app_type] => utility [patent_app_number] => 18/589636 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33454 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20076303 [patent_doc_number] => 12350338 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Biodegradable lipids for the delivery of active agents [patent_app_type] => utility [patent_app_number] => 18/589688 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30887 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19201437 [patent_doc_number] => 20240173336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/432492 [patent_app_country] => US [patent_app_date] => 2024-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18432492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19870303 [patent_doc_number] => 12263140 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-04-01 [patent_title] => Methods of reducing the production of greenhouse gases from animals [patent_app_type] => utility [patent_app_number] => 18/429417 [patent_app_country] => US [patent_app_date] => 2024-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 24 [patent_no_of_words] => 13567 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19196349 [patent_doc_number] => 11993575 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-05-28 [patent_title] => Ethyl [4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]acetate as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/400944 [patent_app_country] => US [patent_app_date] => 2023-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4257 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18400944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19082116 [patent_doc_number] => 20240108917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => METHODS OF TREATING CANCER WITH DRUGS [patent_app_type] => utility [patent_app_number] => 18/540651 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032451 [patent_doc_number] => 20240082266 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING EYES AND METHODS OF PREPARATION [patent_app_type] => utility [patent_app_number] => 18/509800 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19825 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19151184 [patent_doc_number] => 11976080 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-05-07 [patent_title] => Benzofuro[3,2-c]chromen-6-one compounds as antibacterial agents [patent_app_type] => utility [patent_app_number] => 18/388707 [patent_app_country] => US [patent_app_date] => 2023-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8521 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18388707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19076418 [patent_doc_number] => 11945768 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-02 [patent_title] => 8-(3-flurobenzylideneamino)naphthalene-1,3-disulfonic acid as an antioxidant compound [patent_app_type] => utility [patent_app_number] => 18/385043 [patent_app_country] => US [patent_app_date] => 2023-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3651 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385043 [rel_patent_id] =>[rel_patent_doc_number] =>)